ID   NEUR1_HUMAN             Reviewed;         415 AA.
AC   Q99519;
DT   16-NOV-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1997, sequence version 1.
DT   10-MAY-2017, entry version 178.
DE   RecName: Full=Sialidase-1;
DE            EC=3.2.1.18;
DE   AltName: Full=Acetylneuraminyl hydrolase;
DE   AltName: Full=G9 sialidase;
DE   AltName: Full=Lysosomal sialidase;
DE   AltName: Full=N-acetyl-alpha-neuraminidase 1;
DE   Flags: Precursor;
GN   Name=NEU1; Synonyms=NANH;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], CATALYTIC ACTIVITY, FUNCTION, SUBCELLULAR
RP   LOCATION, TISSUE SPECIFICITY, GLYCOSYLATION, AND VARIANT TYPE II
RP   SIALIDOSIS ARG-91.
RC   TISSUE=Fibroblast;
RX   PubMed=8985184; DOI=10.1101/gad.10.24.3156;
RA   Bonten E.J., van der Spoel A., Fornerod M., Grosveld G., d'Azzo A.;
RT   "Characterization of human lysosomal neuraminidase defines the
RT   molecular basis of the metabolic storage disorder sialidosis.";
RL   Genes Dev. 10:3156-3169(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Monocyte;
RX   PubMed=9020182; DOI=10.1074/jbc.272.7.4549;
RA   Milner C.M., Smith S.V., Carrillo M.B., Taylor G.L., Hollinshead M.,
RA   Campbell R.D.;
RT   "Identification of a sialidase encoded in the human major
RT   histocompatibility complex.";
RL   J. Biol. Chem. 272:4549-4558(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], CATALYTIC ACTIVITY, TISSUE SPECIFICITY,
RP   AND VARIANTS SIALIDOSIS TYR-260 AND PRO-363.
RC   TISSUE=Fibroblast;
RX   PubMed=9054950; DOI=10.1038/ng0397-316;
RA   Pshezhetsky A.V., Richard C., Michaud L., Igdoura S.A., Wang S.,
RA   Elsliger M.-A., Ou J., Leclerc D., Gravel R.A., Dallaire L.,
RA   Potier M.;
RT   "Cloning, expression and chromosomal mapping of human lysosomal
RT   sialidase and characterization of mutations in sialidosis.";
RL   Nat. Genet. 15:316-320(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14656967; DOI=10.1101/gr.1736803;
RA   Xie T., Rowen L., Aguado B., Ahearn M.E., Madan A., Qin S.,
RA   Campbell R.D., Hood L.;
RT   "Analysis of the gene-dense major histocompatibility complex class III
RT   region and its comparison to mouse.";
RL   Genome Res. 13:2621-2636(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Shiina S., Tamiya G., Oka A., Inoko H.;
RT   "Homo sapiens 2,229,817bp genomic DNA of 6p21.3 HLA class I region.";
RL   Submitted (SEP-1999) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain, and Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PROTEIN SEQUENCE OF 48-55, AND GLYCOSYLATION.
RC   TISSUE=Placenta;
RX   PubMed=9480870; DOI=10.1042/bj3300641;
RA   Vinogradova M.V., Michaud L., Mezentsev A.V., Lukong K.E., El-Alfy M.,
RA   Morales C.R., Potier M., Pshezhetsky A.V.;
RT   "Molecular mechanism of lysosomal sialidase deficiency in
RT   galactosialidosis involves its rapid degradation.";
RL   Biochem. J. 330:641-650(1998).
RN   [9]
RP   SUBCELLULAR LOCATION, AND MUTAGENESIS OF TYR-412; GLY-413 AND LEU-415.
RX   PubMed=11571282; DOI=10.1074/jbc.M104547200;
RA   Lukong K.E., Seyrantepe V., Landry K., Trudel S., Ahmad A., Gahl W.A.,
RA   Lefrancois S., Morales C.R., Pshezhetsky A.V.;
RT   "Intracellular distribution of lysosomal sialidase is controlled by
RT   the internalization signal in its cytoplasmic tail.";
RL   J. Biol. Chem. 276:46172-46181(2001).
RN   [10]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-352.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [12]
RP   CHARACTERIZATION OF VARIANTS SIALIDOSIS VAL-68; GLY-182; ARG-227;
RP   TYR-260; PHE-270; VAL-298; SER-328 AND PRO-363.
RX   PubMed=10767332; DOI=10.1093/hmg/9.7.1075;
RA   Lukong K.E., Elsliger M.-A., Chang Y., Richard C., Thomas G.,
RA   Carey W., Tylki-Szymanska A., Czartoryska B., Buchholz T.,
RA   Rodriguez Criado G., Palmeri S., Pshezhetsky A.V.;
RT   "Characterization of the sialidase molecular defects in sialidosis
RT   patients suggests the structural organization of the lysosomal
RT   multienzyme complex.";
RL   Hum. Mol. Genet. 9:1075-1085(2000).
RN   [13]
RP   VARIANTS SIALIDOSIS MET-54; VAL-68; ARG-91; GLY-182; ALA-219; ARG-227;
RP   HIS-231; TYR-260; PRO-270; SER-294; VAL-298; SER-328; GLN-335;
RP   PRO-363; CYS-370 AND HIS-TYR-400 INS.
RX   PubMed=11063730; DOI=10.1093/hmg/9.18.2715;
RA   Bonten E.J., Arts W.F., Beck M., Covanis A., Donati M.A., Parini R.,
RA   Zammarchi E., d'Azzo A.;
RT   "Novel mutations in lysosomal neuraminidase identify functional
RT   domains and determine clinical severity in sialidosis.";
RL   Hum. Mol. Genet. 9:2715-2725(2000).
RN   [14]
RP   VARIANTS SIALIDOSIS MET-217 AND ARG-243, AND CHARACTERIZATION OF
RP   VARIANTS SIALIDOSIS MET-217 AND ARG-243.
RX   PubMed=10944856; DOI=10.1007/s100380070034;
RA   Naganawa Y., Itoh K., Shimmoto M., Takiguchi K., Doi H., Nishizawa Y.,
RA   Kobayashi T., Kamei S., Lukong K.E., Pshezhetsky A.V., Sakuraba H.;
RT   "Molecular and structural studies of Japanese patients with sialidosis
RT   type 1.";
RL   J. Hum. Genet. 45:241-249(2000).
RN   [15]
RP   VARIANTS SIALIDOSIS VAL-68; GLY-182; ARG-227; ARG-240; TYR-260;
RP   PHE-270; VAL-298; SER-328 AND PRO-363, AND CHARACTERIZATION OF
RP   VARIANTS SIALIDOSIS VAL-68; GLY-182; ARG-227; TYR-260; PHE-270;
RP   VAL-298; SER-328 AND PRO-363.
RX   PubMed=11279074; DOI=10.1074/jbc.M100460200;
RA   Lukong K.E., Landry K., Elsliger M.-A., Chang Y., Lefrancois S.,
RA   Morales C.R., Pshezhetsky A.V.;
RT   "Mutations in sialidosis impair sialidase binding to the lysosomal
RT   multienzyme complex.";
RL   J. Biol. Chem. 276:17286-17290(2001).
RN   [16]
RP   VARIANTS SIALIDOSIS LEU-80; ARG-240 AND SER-316.
RX   PubMed=11829139; DOI=10.1007/s10038-002-8652-7;
RA   Itoh K., Naganawa Y., Matsuzawa F., Aikawa S., Doi H., Sasagasako N.,
RA   Yamada T., Kira J., Kobayashi T., Pshezhetsky A.V., Sakuraba H.;
RT   "Novel missense mutations in the human lysosomal sialidase gene in
RT   sialidosis patients and prediction of structural alterations of mutant
RT   enzymes.";
RL   J. Hum. Genet. 47:29-37(2002).
RN   [17]
RP   VARIANTS SIALIDOSIS PRO-225; VAL-298 AND GLY-341, CATALYTIC ACTIVITY,
RP   SUBCELLULAR LOCATION, AND CHARACTERIZATION OF VARIANTS SIALIDOSIS
RP   PRO-225; VAL-298 AND GLY-341.
RX   PubMed=14695530; DOI=10.1002/humu.10278;
RA   Pattison S., Pankarican M., Rupar C.A., Graham F.L., Igdoura S.A.;
RT   "Five novel mutations in the lysosomal sialidase gene (NEU1) in type
RT   II sialidosis patients and assessment of their impact on enzyme
RT   activity and intracellular targeting using adenovirus-mediated
RT   expression.";
RL   Hum. Mutat. 23:32-39(2004).
CC   -!- FUNCTION: Catalyzes the removal of sialic acid (N-acetylneuraminic
CC       acid) moities from glycoproteins and glycolipids. To be active, it
CC       is strictly dependent on its presence in the multienzyme complex.
CC       Appears to have a preference for alpha 2-3 and alpha 2-6 sialyl
CC       linkage. {ECO:0000269|PubMed:8985184}.
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of alpha-(2->3)-, alpha-(2->6)-,
CC       alpha-(2->8)- glycosidic linkages of terminal sialic acid residues
CC       in oligosaccharides, glycoproteins, glycolipids, colominic acid
CC       and synthetic substrates. {ECO:0000269|PubMed:14695530,
CC       ECO:0000269|PubMed:8985184, ECO:0000269|PubMed:9054950}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       pH dependence:
CC         Optimum pH is 4.6.;
CC   -!- SUBUNIT: Interacts with cathepsin A (protective protein), beta-
CC       galactosidase and N-acetylgalactosamine-6-sulfate sulfatase in a
CC       multienzyme complex.
CC   -!- INTERACTION:
CC       O43889-2:CREB3; NbExp=3; IntAct=EBI-721517, EBI-625022;
CC   -!- SUBCELLULAR LOCATION: Lysosome membrane; Peripheral membrane
CC       protein; Lumenal side. Lysosome lumen. Cell membrane. Cytoplasmic
CC       vesicle. Note=Localized not only on the inner side of the
CC       lysosomal membrane and in the lysosomal lumen, but also on the
CC       plasma membrane and in intracellular vesicles.
CC   -!- TISSUE SPECIFICITY: Highly expressed in pancreas, followed by
CC       skeletal muscle, kidney, placenta, heart, lung and liver. Weakly
CC       expressed in brain. {ECO:0000269|PubMed:8985184,
CC       ECO:0000269|PubMed:9054950}.
CC   -!- DOMAIN: A C-terminal internalization signal (YGTL) appears to
CC       allow the targeting of plasma membrane proteins to endosomes.
CC   -!- PTM: N-glycosylated. {ECO:0000269|PubMed:19159218,
CC       ECO:0000269|PubMed:8985184, ECO:0000269|PubMed:9480870}.
CC   -!- PTM: Phosphorylation of tyrosine within the internalization signal
CC       results in inhibition of sialidase internalization and blockage on
CC       the plasma membrane.
CC   -!- DISEASE: Sialidosis (SIALIDOSIS) [MIM:256550]: Lysosomal storage
CC       disease occurring as two types with various manifestations. Type 1
CC       sialidosis (cherry red spot-myoclonus syndrome or normosomatic
CC       type) is late-onset and it is characterized by the formation of
CC       cherry red macular spots in childhood, progressive debilitating
CC       myoclonus, insiduous visual loss and rarely ataxia. The diagnosis
CC       can be confirmed by the screening of the urine for
CC       sialyloligosaccharides. Type 2 sialidosis (also known as
CC       dysmorphic type) occurs as several variants of increasing severity
CC       with earlier age of onset. It is characterized by the presence of
CC       abnormal somatic features including coarse facies and dysostosis
CC       multiplex, vertebral deformities, mental retardation, cherry-red
CC       spot/myoclonus, sialuria, cytoplasmic vacuolation of peripheral
CC       lymphocytes, bone marrow cells and conjunctival epithelial cells.
CC       {ECO:0000269|PubMed:10767332, ECO:0000269|PubMed:10944856,
CC       ECO:0000269|PubMed:11063730, ECO:0000269|PubMed:11279074,
CC       ECO:0000269|PubMed:11829139, ECO:0000269|PubMed:14695530,
CC       ECO:0000269|PubMed:8985184, ECO:0000269|PubMed:9054950}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- SIMILARITY: Belongs to the glycosyl hydrolase 33 family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Neuraminidase entry;
CC       URL="https://en.wikipedia.org/wiki/Neuraminidase";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF040958; AAB96774.1; -; mRNA.
DR   EMBL; X78687; CAA55356.1; -; mRNA.
DR   EMBL; U84246; AAD09239.1; -; mRNA.
DR   EMBL; AF134726; AAD21814.1; -; Genomic_DNA.
DR   EMBL; BA000025; BAB63297.1; -; Genomic_DNA.
DR   EMBL; BT007206; AAP35870.1; -; mRNA.
DR   EMBL; BC000722; AAH00722.1; -; mRNA.
DR   EMBL; BC011900; AAH11900.1; -; mRNA.
DR   CCDS; CCDS4723.1; -.
DR   RefSeq; NP_000425.1; NM_000434.3.
DR   UniGene; Hs.520037; -.
DR   ProteinModelPortal; Q99519; -.
DR   BioGrid; 110831; 13.
DR   IntAct; Q99519; 9.
DR   MINT; MINT-1389413; -.
DR   STRING; 9606.ENSP00000364782; -.
DR   BindingDB; Q99519; -.
DR   ChEMBL; CHEMBL2726; -.
DR   DrugBank; DB00198; Oseltamivir.
DR   CAZy; GH33; Glycoside Hydrolase Family 33.
DR   iPTMnet; Q99519; -.
DR   PhosphoSitePlus; Q99519; -.
DR   BioMuta; NEU1; -.
DR   DMDM; 17368612; -.
DR   EPD; Q99519; -.
DR   MaxQB; Q99519; -.
DR   PaxDb; Q99519; -.
DR   PeptideAtlas; Q99519; -.
DR   PRIDE; Q99519; -.
DR   DNASU; 4758; -.
DR   Ensembl; ENST00000229725; ENSP00000229725; ENSG00000184494.
DR   Ensembl; ENST00000375631; ENSP00000364782; ENSG00000204386.
DR   Ensembl; ENST00000411774; ENSP00000399309; ENSG00000234846.
DR   Ensembl; ENST00000422978; ENSP00000408957; ENSG00000227129.
DR   Ensembl; ENST00000423382; ENSP00000401067; ENSG00000228691.
DR   Ensembl; ENST00000434496; ENSP00000409489; ENSG00000234343.
DR   Ensembl; ENST00000437432; ENSP00000403720; ENSG00000223957.
DR   Ensembl; ENST00000439648; ENSP00000408207; ENSG00000227315.
DR   GeneID; 4758; -.
DR   KEGG; hsa:4758; -.
DR   UCSC; uc003nxq.5; human.
DR   CTD; 4758; -.
DR   DisGeNET; 4758; -.
DR   GeneCards; NEU1; -.
DR   HGNC; HGNC:7758; NEU1.
DR   HPA; HPA015634; -.
DR   HPA; HPA021506; -.
DR   MalaCards; NEU1; -.
DR   MIM; 256550; phenotype.
DR   MIM; 608272; gene.
DR   neXtProt; NX_Q99519; -.
DR   OpenTargets; ENSG00000204386; -.
DR   Orphanet; 93400; Congenital sialidosis type 2.
DR   Orphanet; 93399; Juvenile sialidosis type 2.
DR   Orphanet; 812; Sialidosis type 1.
DR   PharmGKB; PA31560; -.
DR   eggNOG; ENOG410IE33; Eukaryota.
DR   eggNOG; COG4409; LUCA.
DR   GeneTree; ENSGT00720000108878; -.
DR   HOGENOM; HOG000007651; -.
DR   HOVERGEN; HBG057314; -.
DR   InParanoid; Q99519; -.
DR   KO; K01186; -.
DR   OMA; RNQYTES; -.
DR   OrthoDB; EOG091G0HAW; -.
DR   PhylomeDB; Q99519; -.
DR   TreeFam; TF331063; -.
DR   BRENDA; 3.2.1.18; 2681.
DR   Reactome; R-HSA-1660662; Glycosphingolipid metabolism.
DR   Reactome; R-HSA-4085001; Sialic acid metabolism.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   SABIO-RK; Q99519; -.
DR   ChiTaRS; NEU1; human.
DR   GeneWiki; NEU1; -.
DR   GenomeRNAi; 4758; -.
DR   PRO; PR:Q99519; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   Bgee; ENSG00000184494; -.
DR   CleanEx; HS_NEU1; -.
DR   ExpressionAtlas; Q99519; baseline and differential.
DR   Genevisible; Q99519; HS.
DR   GO; GO:0030054; C:cell junction; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0043202; C:lysosomal lumen; TAS:Reactome.
DR   GO; GO:0005765; C:lysosomal membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005764; C:lysosome; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0035580; C:specific granule lumen; TAS:Reactome.
DR   GO; GO:0052794; F:exo-alpha-(2->3)-sialidase activity; IEA:UniProtKB-EC.
DR   GO; GO:0052795; F:exo-alpha-(2->6)-sialidase activity; IEA:UniProtKB-EC.
DR   GO; GO:0052796; F:exo-alpha-(2->8)-sialidase activity; IEA:UniProtKB-EC.
DR   GO; GO:0004308; F:exo-alpha-sialidase activity; IDA:UniProtKB.
DR   GO; GO:0006689; P:ganglioside catabolic process; IBA:GO_Central.
DR   GO; GO:0006687; P:glycosphingolipid metabolic process; TAS:Reactome.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   GO; GO:0009313; P:oligosaccharide catabolic process; IMP:UniProtKB.
DR   InterPro; IPR026856; Sialidase_fam.
DR   InterPro; IPR011040; Sialidases.
DR   PANTHER; PTHR10628; PTHR10628; 1.
DR   Pfam; PF13088; BNR_2; 1.
DR   SUPFAM; SSF50939; SSF50939; 1.
PE   1: Evidence at protein level;
KW   Carbohydrate metabolism; Cell membrane; Complete proteome;
KW   Cytoplasmic vesicle; Direct protein sequencing; Disease mutation;
KW   Glycoprotein; Glycosidase; Hydrolase; Lipid degradation;
KW   Lipid metabolism; Lysosome; Membrane; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repeat; Signal.
FT   SIGNAL        1     47       {ECO:0000269|PubMed:9480870}.
FT   CHAIN        48    415       Sialidase-1.
FT                                /FTId=PRO_0000012026.
FT   REPEAT      112    123       BNR 1.
FT   REPEAT      172    183       BNR 2.
FT   REPEAT      231    242       BNR 3.
FT   REPEAT      347    358       BNR 4.
FT   MOTIF        77     80       FRIP motif.
FT   MOTIF       412    415       Internalization signal.
FT   ACT_SITE    103    103       Proton acceptor. {ECO:0000250}.
FT   ACT_SITE    370    370       Nucleophile. {ECO:0000250}.
FT   ACT_SITE    394    394       {ECO:0000255}.
FT   BINDING      78     78       Substrate. {ECO:0000250}.
FT   BINDING      97     97       Substrate. {ECO:0000250}.
FT   BINDING     264    264       Substrate. {ECO:0000250}.
FT   BINDING     280    280       Substrate. {ECO:0000250}.
FT   BINDING     341    341       Substrate. {ECO:0000250}.
FT   CARBOHYD    186    186       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    343    343       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    352    352       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19159218}.
FT   VARIANT      54     54       V -> M (in SIALIDOSIS; type 1; mild
FT                                mutation as residual activity is still
FT                                measurable).
FT                                {ECO:0000269|PubMed:11063730}.
FT                                /FTId=VAR_012207.
FT   VARIANT      68     68       G -> V (in SIALIDOSIS; type 2; less than
FT                                10% of activity).
FT                                {ECO:0000269|PubMed:10767332,
FT                                ECO:0000269|PubMed:11063730,
FT                                ECO:0000269|PubMed:11279074}.
FT                                /FTId=VAR_012208.
FT   VARIANT      80     80       P -> L (in SIALIDOSIS; type 2; no enzyme
FT                                activity; retained in the endoplasmic
FT                                reticulum / Golgi or rapidly degraded in
FT                                the lysosomes; dbSNP:rs104893985).
FT                                {ECO:0000269|PubMed:11829139}.
FT                                /FTId=VAR_017460.
FT   VARIANT      88     88       G -> A (in dbSNP:rs34712643).
FT                                /FTId=VAR_049203.
FT   VARIANT      91     91       L -> R (in SIALIDOSIS; type 2;
FT                                dbSNP:rs104893972).
FT                                {ECO:0000269|PubMed:11063730,
FT                                ECO:0000269|PubMed:8985184}.
FT                                /FTId=VAR_012209.
FT   VARIANT     182    182       S -> G (in SIALIDOSIS; type 1; normally
FT                                processed; dbSNP:rs398123392).
FT                                {ECO:0000269|PubMed:10767332,
FT                                ECO:0000269|PubMed:11063730,
FT                                ECO:0000269|PubMed:11279074}.
FT                                /FTId=VAR_012210.
FT   VARIANT     217    217       V -> M (in SIALIDOSIS; type 1; partial
FT                                transport and residual transport
FT                                activity; dbSNP:rs28940583).
FT                                {ECO:0000269|PubMed:10944856}.
FT                                /FTId=VAR_012211.
FT   VARIANT     219    219       G -> A (in SIALIDOSIS; type 1; unable to
FT                                reach the lysosomes; dbSNP:rs754068739).
FT                                {ECO:0000269|PubMed:11063730}.
FT                                /FTId=VAR_012212.
FT   VARIANT     225    225       R -> P (in SIALIDOSIS; type 2; impaired
FT                                enzyme folding; dbSNP:rs28940584).
FT                                {ECO:0000269|PubMed:14695530}.
FT                                /FTId=VAR_018076.
FT   VARIANT     227    227       G -> R (in SIALIDOSIS; type 1 and
FT                                juvenile type 2; catalytically inactive;
FT                                retained in pre-lysosomal compartments;
FT                                dbSNP:rs769765227).
FT                                {ECO:0000269|PubMed:10767332,
FT                                ECO:0000269|PubMed:11063730,
FT                                ECO:0000269|PubMed:11279074}.
FT                                /FTId=VAR_012213.
FT   VARIANT     231    231       L -> H (in SIALIDOSIS; type 1; unable to
FT                                reach the lysosomes; dbSNP:rs762400331).
FT                                {ECO:0000269|PubMed:11063730}.
FT                                /FTId=VAR_012214.
FT   VARIANT     240    240       W -> R (in SIALIDOSIS; type 2; no enzyme
FT                                activity; retained in the endoplasmic
FT                                reticulum / Golgi or rapidly degraded in
FT                                the lysosomes; dbSNP:rs104893978).
FT                                {ECO:0000269|PubMed:11279074,
FT                                ECO:0000269|PubMed:11829139}.
FT                                /FTId=VAR_012215.
FT   VARIANT     243    243       G -> R (in SIALIDOSIS; type 1; no enzyme
FT                                activity and no transport to the
FT                                lysosome; dbSNP:rs104893983).
FT                                {ECO:0000269|PubMed:10944856}.
FT                                /FTId=VAR_012216.
FT   VARIANT     260    260       F -> Y (in SIALIDOSIS; infantile type 2;
FT                                catalytically inactive; rapid
FT                                intralysosomal degradation;
FT                                dbSNP:rs104893977).
FT                                {ECO:0000269|PubMed:10767332,
FT                                ECO:0000269|PubMed:11063730,
FT                                ECO:0000269|PubMed:11279074,
FT                                ECO:0000269|PubMed:9054950}.
FT                                /FTId=VAR_012217.
FT   VARIANT     270    270       L -> F (in SIALIDOSIS; type 2; reduction
FT                                in enzyme activity; rapid intralysosomal
FT                                degradation).
FT                                {ECO:0000269|PubMed:10767332,
FT                                ECO:0000269|PubMed:11279074}.
FT                                /FTId=VAR_012219.
FT   VARIANT     270    270       L -> P (in SIALIDOSIS).
FT                                {ECO:0000269|PubMed:11063730}.
FT                                /FTId=VAR_012218.
FT   VARIANT     294    294       R -> S (in SIALIDOSIS; type 1; mild
FT                                mutation as residual activity is still
FT                                measurable; dbSNP:rs190549838).
FT                                {ECO:0000269|PubMed:11063730}.
FT                                /FTId=VAR_012220.
FT   VARIANT     298    298       A -> V (in SIALIDOSIS; type 2; less than
FT                                10% of activity; rapid intralysosomal
FT                                degradation; impaired enzyme folding;
FT                                dbSNP:rs104893981).
FT                                {ECO:0000269|PubMed:10767332,
FT                                ECO:0000269|PubMed:11063730,
FT                                ECO:0000269|PubMed:11279074,
FT                                ECO:0000269|PubMed:14695530}.
FT                                /FTId=VAR_012221.
FT   VARIANT     316    316       P -> S (in SIALIDOSIS; type 1; no enzyme
FT                                activity; retained in the endoplasmic
FT                                reticulum / Golgi or rapidly degraded in
FT                                the lysosomes; dbSNP:rs104893979).
FT                                {ECO:0000269|PubMed:11829139}.
FT                                /FTId=VAR_017461.
FT   VARIANT     328    328       G -> S (in SIALIDOSIS; type 1; reduction
FT                                in enzyme activity; dbSNP:rs534846786).
FT                                {ECO:0000269|PubMed:10767332,
FT                                ECO:0000269|PubMed:11063730,
FT                                ECO:0000269|PubMed:11279074}.
FT                                /FTId=VAR_012222.
FT   VARIANT     335    335       P -> Q (in SIALIDOSIS; type 2; unable to
FT                                reach the lysosomes; dbSNP:rs749996046).
FT                                {ECO:0000269|PubMed:11063730}.
FT                                /FTId=VAR_012223.
FT   VARIANT     341    341       R -> G (in SIALIDOSIS; type 2; affects
FT                                substrate binding or catalysis;
FT                                dbSNP:rs751458617).
FT                                {ECO:0000269|PubMed:14695530}.
FT                                /FTId=VAR_018077.
FT   VARIANT     363    363       L -> P (in SIALIDOSIS; infantile type 2;
FT                                unable to reach the lysosomes;
FT                                dbSNP:rs193922915).
FT                                {ECO:0000269|PubMed:10767332,
FT                                ECO:0000269|PubMed:11063730,
FT                                ECO:0000269|PubMed:11279074,
FT                                ECO:0000269|PubMed:9054950}.
FT                                /FTId=VAR_012224.
FT   VARIANT     370    370       Y -> C (in SIALIDOSIS; infantile type 2;
FT                                catalytically inactive).
FT                                {ECO:0000269|PubMed:11063730}.
FT                                /FTId=VAR_012225.
FT   VARIANT     400    400       Y -> YHY (in SIALIDOSIS; type 1; mild
FT                                mutation as residual activity is still
FT                                measurable).
FT                                /FTId=VAR_012226.
FT   MUTAGEN     412    412       Y->A: Correct sorting to the plasma
FT                                membrane but no endocytosis and
FT                                internalization.
FT                                {ECO:0000269|PubMed:11571282}.
FT   MUTAGEN     413    413       G->A: Correct sorting to the plasma
FT                                membrane but no endocytosis and
FT                                internalization.
FT                                {ECO:0000269|PubMed:11571282}.
FT   MUTAGEN     415    415       L->A: Correct sorting to the plasma
FT                                membrane but no endocytosis and
FT                                internalization.
FT                                {ECO:0000269|PubMed:11571282}.
SQ   SEQUENCE   415 AA;  45467 MW;  360E60A256DEA07F CRC64;
     MTGERPSTAL PDRRWGPRIL GFWGGCRVWV FAAIFLLLSL AASWSKAEND FGLVQPLVTM
     EQLLWVSGRQ IGSVDTFRIP LITATPRGTL LAFAEARKMS SSDEGAKFIA LRRSMDQGST
     WSPTAFIVND GDVPDGLNLG AVVSDVETGV VFLFYSLCAH KAGCQVASTM LVWSKDDGVS
     WSTPRNLSLD IGTEVFAPGP GSGIQKQREP RKGRLIVCGH GTLERDGVFC LLSDDHGASW
     RYGSGVSGIP YGQPKQENDF NPDECQPYEL PDGSVVINAR NQNNYHCHCR IVLRSYDACD
     TLRPRDVTFD PELVDPVVAA GAVVTSSGIV FFSNPAHPEF RVNLTLRWSF SNGTSWRKET
     VQLWPGPSGY SSLATLEGSM DGEEQAPQLY VLYEKGRNHY TESISVAKIS VYGTL
//
